News Releases

Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

TEL AVIV, Israel, April 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in the Aegis Virtual Conference being held May 2May 4, 2023. Chemomab management will present a corporate overview on Wednesday, May 3, 2023.

Aegis 2023 Virtual Investor Conference

Date: 

May 3, 2023 

Time:

9:00am EDT

Venue:

Virtual

Format:

Webcast -- Corporate overview

Presenter:

Senior management

Webcast Link:

https://us02web.zoom.us/j/81590540881

Information: 

mschiavellojr@aegiscap.com

In addition, Chemomab reported that its corporate development team will be in Boston June 5-8, 2023, participating in the BIO International Convention's One-on-One Partnering™ event. Registered attendees can click here to log in and schedule a meeting with Chemomab.

About Chemomab Therapeutics
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury were recently reported. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing and a Phase 2 systemic sclerosis trial is expected to begin around midyear. For more information on Chemomab, visit chemomab.com.

Contacts: 




Investors: 

Investors & Media:

Irina Koffler

Barbara Lindheim

LifeSci Advisors, LLC

Chemomab Therapeutics

Phone: +1 (917) 734-7387

Consulting Vice President, Investor & Public Relations

ir@chemomab.com

Strategic Communications 


barbara.lindheim@chemomab.com

 

SOURCE Chemomab Therapeutics, Ltd.